Targeting the MLL complex in castration-resistant prostate cancer

被引：152

作者：

Malik, Rohit ^{[1
,2
]}

Khan, Amjad P. ^{[1
,2
]}

Asangani, Irfan A. ^{[1
,2
]}

Cieslik, Marcin ^{[1
,2
]}

Prensner, John R. ^{[1
,2
]}

Wang, Xiaoju ^{[1
,2
]}

Iyer, Matthew K. ^{[1
,2
]}

Jiang, Xia ^{[1
,2
]}

Borkin, Dmitry ^{[2
]}

Escara-Wilke, June ^{[1
,2
]}

Stender, Rachell ^{[1
,2
]}

Wu, Yi-Mi ^{[1
,2
]}

Niknafs, Yashar S. ^{[1
]}

Jing, Xiaojun ^{[1
,2
]}

Qiao, Yuanyuan ^{[1
,2
]}

Palanisamy, Nallasivam ^{[1
,2
,3
]}

Kunju, Lakshmi P. ^{[1
,2
,4
]}

Krishnamurthy, Pranathi M. ^{[1
]}

Yocum, Anastasia K. ^{[1
]}

Mellacheruvu, Dattatreya ^{[2
,5
]}

Nesvizhskii, Alexey I. ^{[1
,2
,5
]}

Cao, Xuhong ^{[1
,6
]}

Dhanasekaran, Saravana M. ^{[1
,2
]}

Feng, Felix Y. ^{[1
,7
,8
]}

Grembecka, Jolanta ^{[2
]}

Cierpicki, Tomasz ^{[2
]}

Chinnaiyan, Arul M. ^{[1
,2
,4
,5
,6
,8
]}

机构：

[1] Univ Michigan, Michigan Ctr Translat Pathol, Ann Arbor, MI 48109 USA

[2] Univ Michigan, Dept Pathol, Ann Arbor, MI 48109 USA

[3] Henry Ford Hlth Syst, Dept Urol, Detroit, MI USA

[4] Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA

[5] Univ Michigan, Dept Computat Med & Bioinformat, Ann Arbor, MI 48109 USA

[6] Univ Michigan, Howard Hughes Med Inst, Ann Arbor, MI 48109 USA

[7] Univ Michigan, Radiat Oncol, Ann Arbor, MI 48109 USA

[8] Univ Michigan, Dept Urol, Ann Arbor, MI 48109 USA

来源：

NATURE MEDICINE | 2015年 / 21卷 / 04期

基金：

美国国家卫生研究院;

关键词：

ANDROGEN-RECEPTOR; INCREASED SURVIVAL; MENIN; GENE; EXPRESSION; PROTEINS; ANTIANDROGEN; CELLS;

D O I：

10.1038/nm.3830

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Resistance to androgen deprivation therapies and increased androgen receptor (AR) activity are major drivers of castrationresistant prostate cancer (CRPC). Although prior work has focused on targeting AR directly, co-activators of AR signaling, which may represent new therapeutic targets, are relatively underexplored. Here we demonstrate that the mixed-lineage leukemia protein (MLL) complex, a well-known driver of MLL fusion-positive leukemia, acts as a co-activator of AR signaling. AR directly interacts with the MLL complex via the menin-MLL subunit. Menin expression is higher in CRPC than in both hormone-naive prostate cancer and benign prostate tissue, and high menin expression correlates with poor overall survival of individuals diagnosed with prostate cancer. Treatment with a small-molecule inhibitor of menin-MLL interaction blocks AR signaling and inhibits the growth of castration-resistant tumors in vivo in mice. Taken together, this work identifies the MLL complex as a crucial co-activator of AR and a potential therapeutic target in advanced prostate cancer.

引用

页码：344 / +

页数：11

共 50 条

[41] Strategies in castration-resistant prostate cancer
Bessede, Th
PROGRES EN UROLOGIE, 2011, 21 : S68 - S71
[42] Steroidogenesis in castration-resistant prostate cancer
Shiota, Masaki
Endo, Satoshi
Blas, Leandro
Fujimoto, Naohiro
Eto, Masatoshi
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2023, 41 (05) : 240 - 251
[43] The biology of castration-resistant prostate cancer
Lian, Fei
Sharma, Nitya V.
Moran, Josue D.
Moreno, Carlos S.
CURRENT PROBLEMS IN CANCER, 2015, 39 (01) : 17 - 28
[44] Castration-resistant prostate cancer (CRPC)
Loidl, W.
Luger, F.
Roosen, A.
UROLOGE, 2014, 53 (03): : 391 - 399
[45] Targeting persistent androgen receptor signaling in castration-resistant prostate cancer
Laura Graham
Michael T. Schweizer
Medical Oncology, 2016, 33
[46] Targeting the fibroblast growth factor pathway in molecular subtypes of castration-resistant prostate cancer
Labrecque, Mark P.
Brown, Lisha G.
Coleman, Ilsa M.
Nguyen, Holly M.
Dalrymple, Susan
Brennen, W. Nathaniel
Isaacs, John T.
Li, Dapei
Lakely, Bryce
Delucia, Diana C.
Lee, John K.
Schweizer, Michael T.
Lin, Daniel W.
Corey, Eva
Nelson, Peter S.
Morrissey, Colm
PROSTATE, 2024, 84 (01) : 100 - 110
[47] Castration-resistant prostate cancer (CRPC)
Loidl, W.
Luger, F.
Roosen, A.
UROLOGE, 2014, 53 (03): : 391 - 399
[48] Wntless promotes cellular viability and resistance to enzalutamide in castration-resistant prostate cancer cells
Lombard, Alan P.
Liu, Chengfei
Armstrong, Cameron M.
D'Abronzo, Leandro S.
Lou, Wei
Evans, Christopher P.
Gao, Allen C.
AMERICAN JOURNAL OF CLINICAL AND EXPERIMENTAL UROLOGY, 2019, 7 (04): : 203 - 214
[49] Apalutamide for the treatment of patients with castration-resistant prostate cancer
Hauke, R.
DRUGS OF TODAY, 2018, 54 (10) : 585 - 590
[50] Secondary Hormone Therapy for Castration-Resistant Prostate Cancer
Taplin, Mary-Ellen
ONCOLOGY-NEW YORK, 2013, 27 (05): : 371 - +

← 1 2 3 4 5 →